Design Therapeutics, Inc. DSGN

12.12 (0.24) (1.94%) as of 25 Sep
Market cap
$809.3M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
— — — — — 0.00 — —
P/S ratio
— — — — — 2,377.24 — —
P/FCF ratio
— — — — — 0.00 — —
P/Operating CF
— — — — — (188.91) — —
P/B ratio
— — — — — 0.00 — —
Price to Tangible BV
— — — — — 0.00 — —
EV/Sales
— — — — — 2,217.54 — —
EV/EBITDA
— — — — — 0.00 — —
EV/Operating CF
— — — — — (57.81) — —
EV/FCF
— — — — — (57.81) — —
Quick Ratio
16.84 29.01 29.29 30.66 72.70 15.49 0.02 —
Current Ratio
17.14 29.31 29.58 31.10 72.96 15.55 0.02 —
Net Debt/EBITDA
2.68 3.61 3.37 4.82 10.73 4.30 (0.23) —
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 772.22% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 (0.19) —
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.01 0.00 —
Operating CF/Net income
0.78 0.87 0.88 0.81 0.83 1.05 0.07 —
Capex/Depreciation
0.07 0.06 0.05 0.89 (29.58) 1.15 — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(30.70%) (19.08%) (22.10%) (17.85%) (19.16%) 110.72% 27.37% —
ROA
(29.18%) (18.31%) (21.20%) (17.30%) (16.64%) (45.24%) (4,548.89%) —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(32.97%) (20.58%) (24.17%) (19.40%) (9.31%) (24.37%) 56.22% —
Average Days of Receivables
— — — 0.00 0.00 0.00 — —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2,681.42% 0.00% —
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 1,104.42% 0.00% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 199.12% — —
Graham Net Nets
— — — — — (0.02) — —
Graham Number
— — — — — 2.91 — —
Earnings Yield
— — — — — (1.54%) — —
Free Cash Flow Yield
— — — — — (1.61%) — —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.01 0.00 —
Operating CF per Share
(0.95) (0.76) (1.05) (0.92) (0.64) (0.55) 0.00 —
Capex per Share
0.00 (0.01) 0.00 (0.02) (0.03) 0.00 0.00 —
Free Cash Flow per Share
(0.95) (0.77) (1.05) (0.94) (0.67) (0.55) 0.00 —
Cash per Share
3.83 4.34 5.03 5.93 8.36 2.28 0.00 —
Shareholders Equity per Share
3.71 4.28 4.96 5.88 8.32 (0.72) (0.07) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
3.71 4.28 4.96 5.88 8.32 (0.72) (0.07) —
Free Cash Flow
(54.55) (43.44) (58.82) (52.20) (30.91) (8.74) (0.14) —
Working Capital
210.73 239.58 274.96 324.34 380.15 33.90 (3.64) —
Capital Expenditures
(0.19) (0.34) (0.26) (0.88) (1.54) (0.08) — —
Net Current Asset Value
210.08 238.04 272.63 321.29 377.01 (11.60) (3.64) —
EV/EBIT
— — — — — 0.00 — —
Capex to Sales
0.00 0.00 0.00 0.00 0.00 0.34 — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00% 0.00% (3,663.72%) 0.00% —
Price to Operating Income
— — — — — 0.00 — —
Other line items
Depreciation/Fixed assets
(2.68) (3.97) (3.28) (0.51) 0.03 (0.93) — —
Cash ROIC
(12.80%) (9.13%) (10.77%) (8.10%) (4.03%) (35.28%) 4.84% —
Accounts Receivable Turnover
— — — 0.00 0.00 3.77 — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 — —
Inventory Turnover
— — — 0.00 0.00 0.00 — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 — —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 — —
Average Receivables
— — — 0.61 0.06 0.06 — —
Average Payables
2.25 2.06 2.48 2.32 1.51 1.51 — —
Average Assets
239.15 270.87 315.39 365.85 213.54 18.30 0.05 —
Average Common Equity
227.30 259.89 302.50 354.72 185.41 (7.48) (7.48) —

Fold the line items

Columns are period end dates